U S Dialysis & Related Lab Services With Intersegment was Davita’s largest segment in fiscal 2025, bringing in $11.79B of $13.64B (86%).
| Segment | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S Dialysis & Related Lab Services With Intersegment | $10.60B | $10.94B | $11.39B | $11.79B | ||||||||||||||
| U.S. Dialysis | — | — | — | — | ||||||||||||||
| U.S. Dialysis & Related Lab Services | — | — | — | — | ||||||||||||||
| Guarantor Subsidiaries | — | — | — | — | ||||||||||||||
| Davita Medical Group (Dmg) | — | — | — | — | ||||||||||||||
| Healthcare Partners (Hcp) | — | — | — | — | ||||||||||||||
| Other Operating Segments With Intersegment | $1.10B | $1.30B | $1.51B | $1.92B | ||||||||||||||
| Non-Guarantor Subsidiaries | — | — | — | — | ||||||||||||||
| Other - Ancillary Services | — | — | — | — | ||||||||||||||
| Other Ancillary Services & Strategic Initiatives | — | — | — | — | ||||||||||||||
| Other-Ancillary Services & Strategic Initiatives | — | — | — | — | ||||||||||||||
| Davita Healthcare Partners Inc | — | — | — | — | ||||||||||||||
| Davita Inc | — | — | — | — | ||||||||||||||
| Intersegment Elimination | -$91.24M | -$96.07M | -$85.66M | -$72.16M | ||||||||||||||
| Consolidating Adjustments | — | — | — | — | ||||||||||||||
| Total | $11.61B | $12.14B | $12.82B | $13.64B |
Davita brought in $13.64B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 6.5% from $12.82B in fiscal 2024. U S Dialysis & Related Lab Services With Intersegment was the largest at $11.79B (86.4%), ahead of Other Operating Segments With Intersegment at $1.92B (14.1%).
Compared with fiscal 2024, Other Operating Segments With Intersegment grew 27.3% to $1.92B and U S Dialysis & Related Lab Services With Intersegment grew 3.5% to $11.79B. From fiscal 2022 to 2025, combined revenue from these segments grew from $11.61B to $13.64B, a compound annual growth rate of 5.5%. U S Dialysis & Related Lab Services With Intersegment's share of the total fell from 91.3% to 86.4%.
The total is net of Intersegment Elimination, which took $72.16M off revenue in fiscal 2025.
Davita (DVA) reports its revenue by segment. In fiscal 2025, U S Dialysis & Related Lab Services With Intersegment was its largest segment, bringing in $11.79B (86.4% of the total), followed by Other Operating Segments With Intersegment at $1.92B (14.1%).
U S Dialysis & Related Lab Services With Intersegment was Davita's largest segment in fiscal 2025, bringing in $11.79B, or 86.4% of the $13.64B total across its three segments.
Other Operating Segments With Intersegment grew faster than U S Dialysis & Related Lab Services With Intersegment in fiscal 2025, up 27.3% from $1.51B to $1.92B. U S Dialysis & Related Lab Services With Intersegment grew 3.5% to $11.79B.
Every figure comes from Davita's annual financial filings, as reported. Each line keeps the name Davita gives it, and years follow its fiscal calendar.
Davita's revenue by segment goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.